BJU International最新文献

{"title":"Suggestions for future trials comparing mini‐percutaneous nephrolithotomy and flexible ureteroscopy","authors":"Dongming Ye, Handa Zheng, Jiahui Chen, Qiao Lv, Ping Li, Jiansheng Xiao","doi":"10.1111/bju.16909","DOIUrl":"https://doi.org/10.1111/bju.16909","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"54 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144906130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia","authors":"Kagenori Ito, Keiichiro Mori, Rajeev Kumar, Ravindra B. Sabnis, Bannakij Lojanapiwat, Takahiro Kimura, Shin Egawa","doi":"10.1111/bju.16900","DOIUrl":"https://doi.org/10.1111/bju.16900","url":null,"abstract":"ObjectivesThere are notable regional differences in the incidence and mortality of prostate cancer (PCa), whose underlying causes are arguably complex and multifactorial. In this review, we analysed the epidemiology, clinical characteristics, efficacy and safety of therapeutic drugs, prevalence of treatment and testing, and trends in PCa survival in Asian Urological Association member countries.MethodsTo investigate regional differences in incidence, mortality, and survival, we used the latest data from the GLOBOCAN 2022 edition, CONCORD‐3 study data, and the International Monetary Fund database.ResultsAsian men tend to present with more aggressive forms of PCa than their Caucasian counterparts. Paradoxically, survival outcomes are often better in Asian populations despite their more aggressive disease profiles. According to the GLOBOCAN 2022 data, PCa incidence is the highest in North America, Oceania, and Europe, but the lowest in incidence and mortality in Asian countries, despite varying significantly across these countries. Many developing Asian countries continue to experience rising mortality rates from PCa, largely due to limited access to PCa screening and disparities in healthcare infrastructure. While PCa treatments demonstrate comparable effectiveness in Asian populations to that in global trials, access to these therapies remains highly variable across the Asia–Pacific region, highlighting the need for access to improved healthcare policies and systems. In developing Asian nations, the 5‐year survival rate (5Y‐SR) is shown to be positively correlated with gross domestic product (GDP) per capita, suggesting that economic factors play a key determinant in PCa outcomes in these regions.ConclusionsOur analysis reveals stark disparities between developed and developing Asian countries, particularly in mortality‐to‐incidence ratios, prostate‐specific antigen screening coverage, access to novel therapeutics, and reimbursement policies. Despite medical advances, economic status and health policy infrastructure remain key determinants of PCa outcomes in Asia. Moreover, our analysis of 5Y‐SR relative to GDP per capita underscores the colossal impact of the latter on PCa prognosis.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"10 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Staging metastatic urothelial cancer with Nectin‐4 imaging using Gallium‐68‐N188 PET/CT","authors":"Matthias Miederer, Marc Pretze, Elena Abbate, Andreas Hartig, Joana do Mar Ferreira Machado, Katharina Böhm, Ulrich Sommer, Sebastian Hoberück, Ralph A. Bundschuh, Jörg Kotzerke, Christian Thomas","doi":"10.1111/bju.16901","DOIUrl":"https://doi.org/10.1111/bju.16901","url":null,"abstract":"ObjectiveTo quantify Nectin‐4 expression in tumour lesions using the Nectin‐4‐binding peptide Gallium‐68‐N188 and positron emission tomography (PET)/computed tomography (CT) in patients with advanced or metastasised urothelial cancer eligible for therapy with the Nectin‐4‐directed antibody–drug conjugate enfortumab vedotin, in combination with checkpoint inhibitor pembrolizumab (Ev/P).MethodsIn 10 patients, Nectin‐4 PET/CT imaging was analysed before planned systemic therapy with Ev/P based on standardised uptake value (SUV) measurements and the results were correlated to available microscopic findings on Nectin‐4 immunohistochemistry and to clinical follow‐up.ResultsNectin‐4 PET is suitable for detecting Nectin‐4 expression in tumour lesions and demonstrates heterogeneity in Nectin‐4 expression – for example, between lymph node metastases and organ metastases. PET imaging of Nectin‐4 expression is therefore a potentially clinically relevant method for managing the application of Nectin‐4‐targeted therapies.ConclusionsWe show, as a proof of principle, that Nectin‐4 expression can be detected on imaging and serves as an innovative biomarker for targeted therapy in urothelial cancer. Intra‐individual heterogeneous expression of Nectin‐4 in metastatic sites is frequent.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"25 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The value of maintenance therapy in intermediate‐risk non‐muscle‐invasive bladder cancer","authors":"Paolo Zaurito, Pietro Scilipoti, Mattia Longoni, Alessandro Viti, Mario de Angelis, Alfonso Santangelo, Giovanni Tremolada, Leonardo Quarta, Andrea Cosenza, Angelo Occhi, Armando Galdieri, Natasha Disabato, Michele Brancaccio, Giusy Burgio, Andrea Necchi, Maurizio Colecchia, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Marco Moschini","doi":"10.1111/bju.16905","DOIUrl":"https://doi.org/10.1111/bju.16905","url":null,"abstract":"ObjectiveTo evaluate which subgroups of patients with intermediate‐risk non‐muscle‐invasive bladder cancer (IR‐NMIBC) benefit from maintenance therapy based on the International Bladder Cancer Group (IBCG) risk stratification, as the role of a maintenance course in patients with IR‐NMIBC is debated.Patients and MethodsWe relied on a prospectively maintained database of patients with IR‐NMIBC who received intravesical chemotherapy or Bacillus Calmette–Guérin (BCG) (2010–2023). Patients were stratified according the IBCG prognostic algorithm (no, one to two, and three or more risk factors). All patients received at least six induction instillations after index transurethral resection of bladder tumour. We used 3‐month landmark stacked cumulative incidence and multivariable Cox regression models to assess the benefit from a maintenance course in terms of risk of recurrence and progression according to the IBCG risk groups stratification.ResultsAmong 464 patients, 205 (44%) received BCG treatment and 259 (56%) received intravesical chemotherapy. The median (interquartile range) number of maintenance instillations was 9 (5–11). Over a median follow‐up of 57 months, 139 (30%) patients had a recurrence. Patients with no IBCG risk factors had a similar risk of 5‐year disease recurrence according to treatment duration (7.7% vs 7.3%; hazard ratio [HR] 0.78, 95% confidence interval [CI] 0.49–1.37, for induction only vs induction plus maintenance, respectively), whereas patients with one to two (5‐year risk: 16% vs 13%; HR 0.65, 95% CI 0.48–0.82) or three or more IBCG risk factors (5‐year risk: 21% vs 17%; HR 0.48, 95% CI 0.25–0.85) were associated with lower hazards of recurrence if treated with an induction plus maintenance course.ConclusionsThe IBCG algorithm effectively stratifies patients with IR‐NMIBC by recurrence risk. In this observational cohort, maintenance therapy was associated with lower recurrence rates in patients with one to two or three or more IBCG risk factors, but not in those with no risk factors. These findings suggest that the IBCG stratification may inform risk‐adapted treatment decisions in patients with IR‐NMIBC.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"71 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144901644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient facing resources: a review of their readability in urology journals","authors":"Cait Bleakley, Nicholas Campain, Rosie Cockroft, Jonathan Michelmore, Joseph B. John","doi":"10.1111/bju.16904","DOIUrl":"https://doi.org/10.1111/bju.16904","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"39 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to ‘A mitochondrion‐centric approach to guide treatment de‐escalation in advanced prostate cancer’ by Su et al.","authors":"Bryan Chong, Kenneth Chen","doi":"10.1111/bju.16898","DOIUrl":"https://doi.org/10.1111/bju.16898","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"535 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A mitochondrion‐centric approach to guide treatment de‐escalation in advanced prostate cancer","authors":"Po‐Jung Su, I‐Hung Shao, Yu‐Hsiang Lin","doi":"10.1111/bju.16897","DOIUrl":"https://doi.org/10.1111/bju.16897","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"24 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study","authors":"Karen Chiam, Albert Bang, Visalini Nair‐Shalliker, Michael Caruana, Manish I. Patel, Shomik Sengupta, Ian Vela, Andrew Kneebone, Henry Woo, Michael O'Callaghan, Braden Higgs, Alex Jay, Karen Canfell, David P. Smith","doi":"10.1111/bju.16896","DOIUrl":"https://doi.org/10.1111/bju.16896","url":null,"abstract":"ObjectiveTo describe the patterns of care and factors associated with treatment uptake of localised prostate cancer, using the bi‐national Prostate Cancer Outcomes Registry–Australia and New Zealand (PCOR‐ANZ) database.MethodsData for 36 504 patients, diagnosed between 2015 and 2018, from New Zealand and seven Australian jurisdictions were evaluated. Multinomial logistic regression was performed to identify factors associated with the likelihood of receiving no active treatment, radiotherapy (RT), androgen deprivation therapy (ADT) and combined ADT + RT, compared to radical prostatectomy (RP).ResultsThe most common disease risk group and treatment were intermediate‐risk disease (49.2%) and RP (40.3%). Men with low‐risk disease were mostly managed by no active treatment (81.5%). Compared to men treated with RP, the likelihood of receiving other treatments was higher in residents from regional areas, those from lower socio‐economic status (SES) areas and those diagnosed at regional or public hospitals. Being in the lowest SES group was associated with an odds ratio (OR) of 1.84, (95% confidence interval [CI] 1.67–2.02) of having no active treatment, an OR of 1.53 (95% CI 1.32–1.78) for RT, an OR of 2.66 (95% CI 2.10–3.36) for ADT and an OR of 2.56 (95% CI 2.23–2.93) for ADT + RT.ConclusionsFactors related to SES and hospital provider were associated with treatment choices in localised prostate cancer patients, independent of their age or disease risk classification.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"21 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the ‘2‐Week Wait pathway’ for testicular cancer: a UK audit with national implications","authors":"Mushtaq Hussain, Kanwal Naz, Debashis Sarkar","doi":"10.1111/bju.16906","DOIUrl":"https://doi.org/10.1111/bju.16906","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"25 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144898222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author response to comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.","authors":"Sean A Fletcher, Katarzyna J Macura, Christian P Pavlovich","doi":"10.1111/bju.16869","DOIUrl":"https://doi.org/10.1111/bju.16869","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":" ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}